Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
    • Media
  1. Home
  2. Investors

Press releases

06.01.2022

DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections

The DSMB* considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the clinical trial The...
15.12.2021

Issuance of 2nd tranche of €500,000 of notes convertibles into new shares

DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating...
17.11.2021

DEINOVE invites its shareholders to "Investir Day" on November 23, 2021

The first stage of the Phase II clinical trial continues despite the COVID-19 pandemic in the U.S New development contract signed with DSM...
30.09.2021

DEINOVE presents its financial results and the advancement of its programs for the first half of 2021

Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB) expected in Q4 2021 Strengthening of...
22.09.2021

Adoption of the resolutions at the Shareholders’ Extraordinary General Meeting on September 13, 2021

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...
14.09.2021

Implementation of an agreement of notes convertible into new shares for a maximum nominal amount of €10M. Issuance of a first €500,000 tranche

This new agreement with European Select Growth Opportunities Fund enables the issuance of notes convertible into new shares for a maximum...
25.08.2021

DEINOVE- Third convening to an Extraordinary General Meeting on September 13, 2021

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...
30.06.2021

The ATB-Discover project, led by DEINOVE, IBMM and the LMP of the University of Montpellier, is supported by the European Union and Occitania Region

Co-funded by the European Fund FEDER DEINOVE is intensifying its collaboration with the Max Mousseron Institute of Biomolecules (IBMM) and...
23.06.2021

DEINOVE- Adoption of all the ordinary resolutions at the Shareholders’ Meeting of June 21, 2021

The Extraordinary Shareholders’ Meeting will be convened on third notice at a later date DEINOVE (Euronext Growth Paris: ALDEI), a French...
28.05.2021

DEINOVE- Second convening to a Combined General Meeting on June 21, 2021

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...
  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »

Investors

  • Corporate governance
    • Board of Directors
    • Executive Committee
  • DEINOVE Shares
  • Financial Calendar
  • Documentation Center
    • Financial Reports
    • Investors slide deck
    • Analyst Coverage
    • Number of Shares and Voting Rights
    • Newsletter to Shareholders
    • Shareholders' Meetings
    • Declaration of transactions performed on company securities
    • Liquidity Agreement
    • Public offerings - Documentation
    • Bonds Convertible into Shares (OCA)
  • Press releases
  • Investor relations
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

    

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home